The present invention provides a corneal damage prevention/treatment composition comprising thymosin beta 4 and citric acid or salts of same. The composition can additionally comprise any organic acid selected from acetic acid, ascorbic acid or salts of same. The composition enables the activity of existing thymosin beta 4 to be maintained or increased and thus provides effective treatment for corneal wound. Therefore, the composition can be used as an ophthalmic formulation for corneal damage treatment.
